- Arcturus Therapeutics: FDA clearance for Arcturus Therapeutics phase 1 bird flu vaccine trial November 11, 2024
- CSL/GSK/Sanofi: 193 million USD BARDA contracts for bird flu vaccines October 4, 2024
- Cidara Therapeutics: Workforce to be reduced by 30% to focus on CD388 September 12, 2024
- Cidara Therapeutics: Cidara Therapeutics presents at the H.C. Wainwright 26th Annual Global Investment Conference September 9, 2024
- Vir Biotechnology: Development of antibody VIR-2981 against influenza discontinued August 1, 2024
- CureVac/GSK: GSK acquires full rights to influenza vaccines from CureVac July 3, 2024
- Moderna: BARDA funding for phase 3 trial of H5N1 mRNA vaccine July 2, 2024
- Moderna/BioNTech/Pfizer/GSK/Sanofi: Moderna defends mRNA patent, appeal likely May 17, 2024
- GSK/BioNTech/Pfizer: Additional mRNA litigation April 26, 2024
- Cidara Therapeutics: Cidara Therapeutics reacquires global rights to CD388 from Johnson & Johnson, announces financing of 240 million USD, will proceed with CD388 phase 2b study in autumn 2024 April 24, 2024
- Cidara Therapeutics: Divestiture of rezafungin to focus on Cloudbreak DFC pipeline, including CD388 April 24, 2024
- CureVac/GSK: Start of combined phase 1/2 study for avian influenza (H5N1) mRNA vaccine April 24, 2024
- CureVac/GSK: Promising interim data from mRNA seasonal influenza vaccine phase 2 study April 4, 2024
- SAB Biotherapeutics: Partnership with Naval Medical Research Center for SAB-176 study March 25, 2024
- Vir Biotechnology/GSK: Antibody cooperation ended February 23, 2024
- BioNTech/CureVac: German court voids CureVac patent after BioNTech challenge, stock drops 41% December 19, 2023
- BioNTech/Moderna: EPO revokes Moderna patent in vaccine dispute with BioNTech November 21, 2023
- GSK: GSK sells Haleon shares to sharpen its focus on vaccines and infectious diseases October 7, 2023
- BioNTech/Pfizer: Pfizer and BioNTech resolve mRNA patent lawsuit filed by Promosome October 7, 2023
- Moderna: mRNA-1010 Seasonal Influenza Vaccine phase 3 study successfully completed September 13, 2023
News